ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Bristol-Myers Squibb taps Repare’s CRISPR screens for cancer drug discovery

by Ryan Cross
May 29, 2020 | APPEARED IN VOLUME 98, ISSUE 21

 

Bristol-Myers Squibb will pay Repare Therapeutics $65 million and invest $15 million in the start-up as part of a cancer drug–discovery deal. Some common mutations in cancer cells impair their ability to fix damaged DNA, forcing the cells to rely on alternative DNA repair mechanisms as a crutch. Repare uses CRISPR-Cas9 gene-editing screens to knock out genes, pinpoint the proteins responsible for the crutch, and design small-molecule drugs to target them. The strategy is called synthetic lethality. Repare could earn up to $3 billion in milestone payments from BMS.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment